HYDERABAD: Indian pharma company Dr Reddy's Laboratories has launched Amoxicillin tablets, capsules, and oral suspension in the US market.
The product is a bio-equivalent generic version of Amoxil (Amoxicillin) tablets, capsules, and oral suspension.
The United States Food and Drug Administration (USFDA) has approved Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg), and oral suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml).
Amoxicillin tablets, capsules, and oral suspension are suggested for the treatment of ear, nose, throat, genitourinary tract, skin and skin structure and lower respiratory tract that are due to susceptible strains of designated micro-organisms.
For the 12 months ended June 30, 2012 according to IMS Health, the Amoxil brand and generic tablets (875 mg) has US sales of approximately $22.2 million, capsules ($67.2 m), and oral suspension ($89.5 m).
City-based Dr Reddy's amoxicillin tablets in 500 mg and 875 mg are available in bottle counts of 20 and 100. Amoxicillin capsules in 250 mg and 500 mg are available in bottle counts of 100 and 500. Amoxicillin oral suspension in 200 mg/5 ml and 400 mg/5 ml are available in bottle sizes of 50 ml, 75 ml, and 100 ml. Amoxicillin oral suspension in 125 mg/5 ml and 250 mg/5 ml are available in bottle sizes of 80 ml, 100 ml, and 150 ml.